Multiple Myeloma

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

(MSK/OnCancer Blog) Dec 12, 2017 - At the 2017 meeting, held December 9 to 12 in Atlanta, Memorial Sloan Kettering researchers reported important progress in the treatment of several blood cancers.

read article

Study Shows Survival Benefits For Seeing An NCI Specialist For Multiple Myeloma

(UNC Lineberger) Dec 12, 2017 - Patients with multiple myeloma who saw a specialist at a National Cancer Institute-designated comprehensive Cancer Center had better overall survival than patients who only saw a community oncologist, according to a study from the University of North Carolina Lineberger Comprehensive Cancer Center.

read article

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

(Markets Insider) Dec 12, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.

read article

Celgene CEO: New Therapies For A Certain Type Of Cancer Boost Survival Rates 10-Fold

(CNBC) Dec 11, 2017 - A new approach to treating patients suffering from an aggressive form of blood cancer could increase survival rates 10-fold to 20 years, Celgene CEO Mark Alles told CNBC on Monday.

read article

Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term

(ASH 2017) Dec 12, 2017 - In four clinical trials being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

read press release

Chemotherapy-Free Cancer Treatments Move Closer To Reality

(Forbes) Dec 12, 2017 - CAR T-cell treatments continue to achieve impressive results in treating an ever-increasing variety of cancers, but will they ever be able to completely replace chemotherapy?

read article

ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More

(Xconomy National) Dec 11, 2017 - The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements.

read article

CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients

(Penn Medicine) Dec 11, 2017 - Penn studies that target BCMA show promise.

read press release

Immuno-Oncology Drug Development -- Too Much Of A Good Thing?

(Forbes) Dec 12, 2017 - The annual meeting of the American Society of Hematology (ASH), now wrapping up in Atlanta, has generated a lot of excitement about immuno-oncology treatments like Bluebird Bio and Celgene’s experimental CAR-T targeting multiple myeloma.

read article

Global CAR T Therapy Trial Shows High Rates Of Durable Remission For NHL

(Penn Medicine) Dec 11, 2017 - In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

read press release

Amgen's Kyprolis Improves Overall Survival In Blood Cancer Patients

(Reuters) Dec 11, 2017 - Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.

read article

GSK Hails Progress On Its Most Advanced Cancer Drug

(The Telegraph [UK]) Dec 12, 2017 - Britain's biggest drugmaker GSK has hailed progress on its most advanced cancer drug, as the FTSE 100 firm battles to claw back lost ground in one of the world's most competitive medicines markets.

read article

DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible

(Janssen) Dec 12, 2017 - Phase 3 ALCYONE data showed DARZALEX in combination with bortezomib, melphalan and prednisone meaningfully improved progression-free survival and response rates; data featured as late-breaker at ASH 2017 (Abstract #LBA-4) and published in the New England Journal of Medicine.

read corporate press release

New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma

(Janssen) Dec 11, 2017 - Early data evaluated subcutaneous delivery of DARZALEX in relapsed or refractory multiple myeloma (oral presentation; Abstract #838); new Phase 2 data investigated single-agent DARZALEX for intermediate or high-risk smoldering multiple myeloma (oral presentation; Abstract #510).

read corporate press release

KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

(Amgen) Dec 11, 2017 - Amgen today announced new results showing the positive overall survival (OS) findings from the final analysis of Phase 3 ASPIRE trial.

read corporate press release

GSK Presents Promising New Data For Priority BCMA Asset From Its Emerging Oncology Pipeline At 59th ASH Meeting

(GSK) Dec 11, 2017 - GlaxoSmithKline plc today presented promising new data from the dose expansion phase of the DREAMM-1 study of GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate.

read corporate press release

Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study

(Adaptimmune) Dec 11, 2017 - Adaptimmune Therapeutics plc submitted updated data from its completed pilot study1 of NY-ESO SPEAR T-cell therapy in multiple myeloma patients in the setting of autologous stem cell transplant (ASCT) presented by the main investigator at the annual ASH meeting.

read corporate press release

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

(Yahoo! Finance) Dec 11, 2017 - Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers; preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer.

read article

Bluebird, Celgene Myeloma Therapy Appears to Improve in Time

(Bloomberg) Dec 10, 2017 - A novel therapy from Bluebird Bio Inc. and Celgene Corp. for patients nearing death from an aggressive form of blood cancer appears to get more effective over time, wiping out signs of disease in more than half of those treated in a small trial.

read article

PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting

(PharmaMar) Dec 11, 2017 - PharmaMar has presented positive results from the ADMYRE Phase III pivotal trial of plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.

read corporate press release
Next Page